Oncolytic HSV-1 Engineered to Express Anti-PD-L1 scFv-Fc

3.2 MB of research data from figshare, authored by Naeimeh Roshanzamir and last updated on 2026-05-22. The dataset documents the engineering and functional assessment of an oncolytic herpes simplex virus modified to express an anti-PD-L1 antibody fragment. It includes results from Western blot, ELISA, and flow cytometry experiments evaluating expression, binding, and viral replication across multiple human cancer cell lines.

Use Cases

• Training models to predict viral replication kinetics based on cell line characteristics mentioned in the description
• Analyzing the relationship between PD-L1 surface modulation and cytotoxicity outcomes from the described experiments
• Benchmarking the expression and secretion efficiency of engineered antibody fragments in viral vectors as described

Strengths

• Data is openly licensed under CC-BY-4.0, permitting reuse and redistribution.
• Experimental validation includes multiple assays (Western blot, ELISA, flow cytometry) across three human cancer cell lines (A375, PANC-1, CaSki).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 3.2 MB size suggests a small dataset, potentially limited in scope.

Provenance

Source

figshare, author Naeimeh Roshanzamir

Collection Method

Experimental data from virology and immunology assays, including molecular cloning, viral engineering, and cell-based functional tests.

Freshness

Last updated 2026-05-22 08:17:42; freshness should be verified.